802-2

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug Name802-2
Drug Alias Namecnscqic-cyclicAnti-CD4 802-2802-2
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionT-cell surface antigen CD4 inhibitors
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThomas Jefferson UniversityTheriva Biologics Inc
Active IndicationsN/A
Inactive IndicationsGraft vs Host Disease

Other Information

ATC CodeN/A
Related LinksN/A